article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Such warnings “constitute the pharma response in literally every instance since 1906,” the first drug regulation agency was created, said Dr. Aaron Kesselheim. The post PhRMA lies to protect pharma profits appeared first on World of DTC Marketing.com. Amazon’s operating margin is under 5 percent.

Pharma 255
article thumbnail

An Annex 1 and Pharma 4.0 perspective on water quality

European Pharmaceutical Review

1 The last four are produced at separate plants and thus less discussed for pharma since they are unlikely to be producing them in house. In particular, purified water and WFI are critical when producing sterile pharmaceutical drug products. Water quality from an Annex 1 and Pharma 4.0 Making the journey to PAT and Pharma 4.0.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

When people think about pharma, they often think about “big” pharma: large, faceless corporations. The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We But rare diseases are a particularly important and challenging focus area.

article thumbnail

How to approach die plate adhesion during tableting

European Pharmaceutical Review

1 In pharmaceutical manufacturing, the high level of final product quality is the major driver. Tablets should be defect-free and compliant to good manufacturing practice (GMP) aspects and final-user requirements. Pharmaceutical Technology. Internet] IMA Pharma. International Journal of Food Properties.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

Pierre Socha, partner at Amadeus Capital Partners, London, UK, predicts that larger pharmaceutical companies may have similar interests. Most pharmas will buy biotech companies or smaller pharma groups for the quality of their clinical assets and the drugs on their developments,” he says. ” This $1.5